nafamostat has been researched along with 2019 Novel Coronavirus Disease in 39 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis." | 8.02 | Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. ( Asakura, H; Koba, H; Ogawa, H; Takahashi, W; Tsuji, N; Ueda, T; Yoneda, T, 2021) |
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 5.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| "Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis." | 4.02 | Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. ( Asakura, H; Koba, H; Ogawa, H; Takahashi, W; Tsuji, N; Ueda, T; Yoneda, T, 2021) |
| " Serious adverse events were not observed in either group." | 3.30 | Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial. ( Hagiya, H; Harada, S; Hasegawa, K; Hashimoto, H; Ikeda, M; Ikeuchi, K; Imamura, A; Inoue, JI; Jubishi, D; Kashiwabara, K; Kisimoto, N; Kohsaka, T; Miwa, A; Mizoguchi, A; Moritoyo, T; Moriya, K; Okamoto, K; Okugawa, S; Otsuka, F; Seto, Y; Shimizu, T; Tsutsumi, T, 2023) |
| "Nafamostat was administered as an intravenous infusion at a dose of 0." | 3.11 | Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. ( Akram, AR; Anthony, DC; Antonelli, J; Blyth, KG; Boz, C; Bruce, A; Burgess, M; Church, C; Churchill, GC; Dear, JW; Dhaliwal, K; Dockrell, D; Duncan, A; Ebrahimi, KH; Emanuel, P; Ferrett, C; Findlay, EG; Finlayson, K; Gaughan, EE; Hardisty, G; Hirani, N; Jabbal, S; Koch, O; Li, F; MacKintosh, C; Marshall, ADL; McCullagh, JSO; McNamara, S; Mills, B; Mills, R; Moore, A; Nazarov, IB; Nimmo, AF; Norrie, J; O'Connor, R; Owen, A; Parker, RA; Plant, S; Quinn, TM; Rannard, S; Rinaldi, G; Russell, K; Scholefield, E; Schwarze, J; Shankar-Hari, M; Templeton, K; Valanciute, A; Walsh, T; Young, I, 2022) |
| "The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms." | 2.72 | COVID-19-associated coagulopathy and disseminated intravascular coagulation. ( Asakura, H; Ogawa, H, 2021) |
| "We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19)." | 2.66 | High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. ( Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T, 2020) |
| "Nafamostat and camostat were discovered as covalent inhibitors of TMPRSS2 protease involved in viral entry." | 1.91 | In Silico and In Vitro Evaluation of Some Amidine Derivatives as Hit Compounds towards Development of Inhibitors against Coronavirus Diseases. ( Anvari, A; El-Sayed, SM; Farahat, AA; Gohda, J; Hassan, AHE; Inoue, JI; Kawaguchi, Y; Mansour, RMA; Matsumoto, T; Shirouzu, M; Yamamoto, M, 2023) |
| "Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models." | 1.91 | Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. ( Arshad, U; Box, H; Bramwell, C; Cox, H; Curley, P; Dhaliwal, K; Gallardo-Toledo, E; Herriott, J; Hobson, J; Kijak, E; Kipar, A; Mc Caughan, F; Neary, M; Owen, A; Pertinez, H; Rajoli, RKR; Rannard, S; Sharp, J; Stewart, JP; Tatham, L; Valentijn, A, 2023) |
| "Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking." | 1.72 | Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness. ( Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022) |
| "Critical illnesses associated with coronavirus disease 2019 (COVID-19) are attributable to a hypercoagulable status." | 1.62 | Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate. ( Harada, S; Ikeda, M; Jubishi, D; Kanno, Y; Kurano, M; Moriya, K; Okamoto, K; Okugawa, S; Osawa, I; Otani, A; Shinohara, T; Wakimoto, Y; Yamashita, M; Yatomi, Y, 2021) |
| "Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases." | 1.62 | Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. ( Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A, 2021) |
| "Pretreatment with camostat (0." | 1.56 | Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. ( Deng, X; Kikuchi, A; Nagatomi, R; Nishimura, H; Yamaya, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 39 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 1 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 1 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 1 |
| Peng, S | 1 |
| Shi, Y | 1 |
| Zhang, Z | 1 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 1 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 1 |
| Huang, XP | 1 |
| Liu, Y | 1 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 2 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Choudhry, N | 1 |
| Zhao, X | 1 |
| Xu, D | 1 |
| Zanin, M | 1 |
| Chen, W | 1 |
| Yang, Z | 1 |
| Chen, J | 2 |
| Ianevski, A | 1 |
| Yao, R | 1 |
| Lysvand, H | 1 |
| Grødeland, G | 1 |
| Legrand, N | 1 |
| Oksenych, V | 1 |
| Zusinaite, E | 1 |
| Tenson, T | 1 |
| Bjørås, M | 1 |
| Kainov, DE | 1 |
| Mamun, AA | 1 |
| Akter, F | 1 |
| Khan, M | 1 |
| Ahmed, SS | 1 |
| Uddin, MG | 1 |
| Tasfia, NT | 1 |
| Efaz, FM | 1 |
| Ali, MA | 1 |
| Sultana, MUC | 1 |
| Halim, MA | 1 |
| Mahoney, M | 1 |
| Damalanka, VC | 1 |
| Tartell, MA | 1 |
| Chung, DH | 1 |
| Lourenço, AL | 1 |
| Pwee, D | 1 |
| Mayer Bridwell, AE | 1 |
| Hoffmann, M | 3 |
| Voss, J | 1 |
| Karmakar, P | 1 |
| Azouz, NP | 1 |
| Klingler, AM | 1 |
| Rothlauf, PW | 1 |
| Thompson, CE | 1 |
| Lee, M | 1 |
| Klampfer, L | 1 |
| Stallings, CL | 1 |
| Rothenberg, ME | 1 |
| Pöhlmann, S | 3 |
| Whelan, SPJ | 1 |
| O'Donoghue, AJ | 1 |
| Janetka, JW | 1 |
| Moon, K | 1 |
| Hong, KW | 1 |
| Bae, IG | 1 |
| Yates, AG | 1 |
| Weglinski, CM | 1 |
| Ying, Y | 1 |
| Dunstan, IK | 1 |
| Strekalova, T | 1 |
| Anthony, DC | 2 |
| Krasemann, S | 1 |
| Haferkamp, U | 1 |
| Pfefferle, S | 1 |
| Woo, MS | 1 |
| Heinrich, F | 1 |
| Schweizer, M | 1 |
| Appelt-Menzel, A | 1 |
| Cubukova, A | 1 |
| Barenberg, J | 1 |
| Leu, J | 1 |
| Hartmann, K | 1 |
| Thies, E | 1 |
| Littau, JL | 1 |
| Sepulveda-Falla, D | 1 |
| Zhang, L | 1 |
| Ton, K | 1 |
| Liang, Y | 1 |
| Matschke, J | 1 |
| Ricklefs, F | 1 |
| Sauvigny, T | 1 |
| Sperhake, J | 1 |
| Fitzek, A | 1 |
| Gerhartl, A | 1 |
| Brachner, A | 1 |
| Geiger, N | 1 |
| König, EM | 1 |
| Bodem, J | 1 |
| Franzenburg, S | 1 |
| Franke, A | 1 |
| Moese, S | 1 |
| Müller, FJ | 1 |
| Geisslinger, G | 2 |
| Claussen, C | 2 |
| Kannt, A | 2 |
| Zaliani, A | 3 |
| Gribbon, P | 3 |
| Ondruschka, B | 1 |
| Neuhaus, W | 1 |
| Friese, MA | 1 |
| Glatzel, M | 1 |
| Pless, O | 1 |
| Quinn, TM | 1 |
| Gaughan, EE | 1 |
| Bruce, A | 1 |
| Antonelli, J | 1 |
| O'Connor, R | 1 |
| Li, F | 1 |
| McNamara, S | 1 |
| Koch, O | 1 |
| MacKintosh, C | 1 |
| Dockrell, D | 1 |
| Walsh, T | 1 |
| Blyth, KG | 1 |
| Church, C | 1 |
| Schwarze, J | 1 |
| Boz, C | 1 |
| Valanciute, A | 1 |
| Burgess, M | 1 |
| Emanuel, P | 1 |
| Mills, B | 1 |
| Rinaldi, G | 1 |
| Hardisty, G | 1 |
| Mills, R | 1 |
| Findlay, EG | 1 |
| Jabbal, S | 1 |
| Duncan, A | 1 |
| Plant, S | 1 |
| Marshall, ADL | 1 |
| Young, I | 1 |
| Russell, K | 1 |
| Scholefield, E | 1 |
| Nimmo, AF | 1 |
| Nazarov, IB | 1 |
| Churchill, GC | 1 |
| McCullagh, JSO | 1 |
| Ebrahimi, KH | 1 |
| Ferrett, C | 1 |
| Templeton, K | 1 |
| Rannard, S | 2 |
| Owen, A | 2 |
| Moore, A | 1 |
| Finlayson, K | 1 |
| Shankar-Hari, M | 1 |
| Norrie, J | 1 |
| Parker, RA | 1 |
| Akram, AR | 1 |
| Dear, JW | 1 |
| Hirani, N | 1 |
| Dhaliwal, K | 2 |
| Jäger, N | 1 |
| Krüger, N | 1 |
| Aggarwal, A | 1 |
| Akerman, A | 1 |
| Milogiannakis, V | 1 |
| Silva, MR | 1 |
| Walker, G | 1 |
| Stella, AO | 1 |
| Kindinger, A | 1 |
| Angelovich, T | 1 |
| Waring, E | 1 |
| Amatayakul-Chantler, S | 1 |
| Roth, N | 1 |
| Manni, S | 1 |
| Hauser, T | 1 |
| Barnes, T | 1 |
| Condylios, A | 1 |
| Yeang, M | 1 |
| Wong, M | 1 |
| Jean, T | 1 |
| Foster, CSP | 1 |
| Christ, D | 1 |
| Hoppe, AC | 1 |
| Munier, ML | 1 |
| Darley, D | 1 |
| Churchill, M | 1 |
| Stark, DJ | 1 |
| Matthews, G | 1 |
| Rawlinson, WD | 1 |
| Kelleher, AD | 1 |
| Turville, SG | 1 |
| Ikeda, M | 3 |
| Okugawa, S | 3 |
| Kashiwabara, K | 2 |
| Moritoyo, T | 2 |
| Kanno, Y | 2 |
| Jubishi, D | 3 |
| Hashimoto, H | 2 |
| Okamoto, K | 3 |
| Tsushima, K | 1 |
| Uchida, Y | 1 |
| Mitsumura, T | 1 |
| Igari, H | 1 |
| Tsutsumi, T | 2 |
| Araoka, H | 1 |
| Yatera, K | 1 |
| Yamamoto, Y | 2 |
| Nakamura, Y | 1 |
| Otani, A | 2 |
| Yamashita, M | 2 |
| Wakimoto, Y | 2 |
| Shinohara, T | 2 |
| Adachi-Katayama, M | 1 |
| Oyabu, T | 1 |
| Kanematsu, A | 1 |
| Harada, S | 3 |
| Takeshita, Y | 1 |
| Nakano, Y | 1 |
| Miyazaki, Y | 1 |
| Sakao, S | 1 |
| Saito, M | 1 |
| Ogura, S | 1 |
| Yamasaki, K | 1 |
| Kawasuji, H | 1 |
| Hataji, O | 1 |
| Inoue, JI | 4 |
| Seto, Y | 2 |
| Moriya, K | 3 |
| C, AM | 1 |
| Wessler, S | 1 |
| Ponnuraj, K | 1 |
| Hassan, AHE | 1 |
| El-Sayed, SM | 1 |
| Yamamoto, M | 2 |
| Gohda, J | 2 |
| Matsumoto, T | 1 |
| Shirouzu, M | 1 |
| Kawaguchi, Y | 2 |
| Mansour, RMA | 1 |
| Anvari, A | 1 |
| Farahat, AA | 1 |
| Jeong, JH | 1 |
| Lee, WH | 1 |
| Min, SC | 1 |
| Kim, BK | 1 |
| Park, OB | 1 |
| Chokkakula, S | 1 |
| Ahn, SJ | 1 |
| Oh, S | 1 |
| Park, JH | 1 |
| Jung, JW | 1 |
| Jung, JM | 1 |
| Kim, EG | 1 |
| Song, MS | 1 |
| Kohsaka, T | 1 |
| Shimizu, T | 1 |
| Hagiya, H | 1 |
| Hasegawa, K | 1 |
| Otsuka, F | 1 |
| Miwa, A | 1 |
| Kisimoto, N | 1 |
| Mizoguchi, A | 1 |
| Imamura, A | 1 |
| Ikeuchi, K | 1 |
| Kondo, A | 1 |
| Fujimoto, KJ | 1 |
| Yanai, T | 1 |
| Neary, M | 1 |
| Sharp, J | 1 |
| Gallardo-Toledo, E | 1 |
| Herriott, J | 1 |
| Kijak, E | 1 |
| Bramwell, C | 1 |
| Cox, H | 1 |
| Tatham, L | 1 |
| Box, H | 1 |
| Curley, P | 1 |
| Arshad, U | 1 |
| Rajoli, RKR | 1 |
| Pertinez, H | 1 |
| Valentijn, A | 1 |
| Mc Caughan, F | 1 |
| Hobson, J | 1 |
| Kipar, A | 1 |
| Stewart, JP | 1 |
| Reus, P | 1 |
| Guthmann, H | 1 |
| Uhlig, N | 1 |
| Agbaria, M | 1 |
| Issmail, L | 1 |
| Eberlein, V | 1 |
| Nordling-David, MM | 1 |
| Jbara-Agbaria, D | 1 |
| Ciesek, S | 2 |
| Bojkova, D | 2 |
| Cinatl, J | 2 |
| Burger-Kentischer, A | 1 |
| Rupp, S | 1 |
| Grunwald, T | 1 |
| Golomb, G | 1 |
| Asakura, H | 3 |
| Ogawa, H | 3 |
| Schroeder, S | 1 |
| Kleine-Weber, H | 1 |
| Müller, MA | 1 |
| Drosten, C | 1 |
| Zhou, H | 1 |
| Fang, Y | 1 |
| Xu, T | 1 |
| Ni, WJ | 1 |
| Shen, AZ | 1 |
| Meng, XM | 1 |
| Yamaya, M | 1 |
| Nishimura, H | 1 |
| Deng, X | 1 |
| Kikuchi, A | 1 |
| Nagatomi, R | 1 |
| Jang, S | 1 |
| Rhee, JY | 1 |
| Kiso, M | 1 |
| Sakai-Tagawa, Y | 1 |
| Iwatsuki-Horimoto, K | 1 |
| Imai, M | 1 |
| Takeda, M | 1 |
| Kinoshita, N | 1 |
| Ohmagari, N | 1 |
| Semba, K | 1 |
| Matsuda, Z | 1 |
| Kawaoka, Y | 1 |
| Hifumi, T | 1 |
| Isokawa, S | 1 |
| Otani, N | 1 |
| Ishimatsu, S | 1 |
| Sagawa, T | 1 |
| Inoue, KI | 1 |
| Takano, H | 1 |
| Fujii, H | 1 |
| Tsuji, T | 1 |
| Yuba, T | 1 |
| Tanaka, S | 1 |
| Suga, Y | 1 |
| Matsuyama, A | 1 |
| Omura, A | 1 |
| Shiotsu, S | 1 |
| Takumi, C | 1 |
| Ono, S | 1 |
| Horiguchi, M | 1 |
| Hiraoka, N | 1 |
| Iwasaka, S | 1 |
| Shono, Y | 1 |
| Tokuda, K | 1 |
| Nakashima, K | 1 |
| Maki, J | 1 |
| Nagasaki, Y | 1 |
| Shimono, N | 1 |
| Akahoshi, T | 1 |
| Taguchi, T | 1 |
| Rangel, HR | 1 |
| Ortega, JT | 1 |
| Maksoud, S | 1 |
| Pujol, FH | 1 |
| Serrano, ML | 1 |
| Osawa, I | 1 |
| Kurano, M | 1 |
| Yatomi, Y | 1 |
| Kishk, SM | 1 |
| Kishk, RM | 1 |
| Yassen, ASA | 1 |
| Nafie, MS | 1 |
| Nemr, NA | 1 |
| ElMasry, G | 1 |
| Al-Rejaie, S | 1 |
| Simons, C | 1 |
| Takahashi, W | 1 |
| Yoneda, T | 1 |
| Koba, H | 1 |
| Ueda, T | 1 |
| Tsuji, N | 1 |
| Yuno, A | 1 |
| Kenmotsu, Y | 1 |
| Takahashi, Y | 1 |
| Nomoto, H | 1 |
| Kameda, H | 1 |
| Cho, KY | 1 |
| Nakamura, A | 1 |
| Yamashita, Y | 1 |
| Nakamura, J | 1 |
| Nakakubo, S | 1 |
| Kamada, K | 1 |
| Suzuki, M | 1 |
| Sugino, H | 1 |
| Inoshita, N | 1 |
| Konno, S | 1 |
| Miyoshi, H | 1 |
| Atsumi, T | 1 |
| Sawamura, Y | 1 |
| Shimatsu, A | 1 |
| Ramakrishnan, J | 1 |
| Kandasamy, S | 1 |
| Iruthayaraj, A | 1 |
| Magudeeswaran, S | 1 |
| Chinnasamy, K | 1 |
| Poomani, K | 1 |
| Ellinger, B | 1 |
| Westhaus, S | 1 |
| Keminer, O | 1 |
| Reinshagen, J | 1 |
| Kuzikov, M | 1 |
| Wolf, M | 1 |
| Dai, L | 1 |
| Barrett, L | 1 |
| James, J | 1 |
| Plaisance-Bonstaff, K | 1 |
| Post, SR | 1 |
| Qin, Z | 1 |
| Huang, X | 1 |
| Pearce, R | 1 |
| Omenn, GS | 1 |
| Zhang, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial[NCT04418128] | Phase 2/Phase 3 | 84 participants (Anticipated) | Interventional | 2020-06-10 | Not yet recruiting | ||
| DEFINE - Evaluating Therapies for COVID-19[NCT04473053] | Phase 1/Phase 2 | 200 participants (Anticipated) | Interventional | 2020-07-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
4 reviews available for nafamostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, | 2020 |
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En | 2020 |
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus | 2020 |
COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Topics: Adult; Anticoagulants; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Tests; COVID-19; | 2021 |
4 trials available for nafamostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
Topics: Benzamidines; COVID-19; Guanidines; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topi | 2021 |
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2022 |
Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.
Topics: Antiviral Agents; COVID-19; Disease Progression; Humans; SARS-CoV-2; Single-Blind Method; Treatment | 2023 |
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Topics: Antiviral Agents; COVID-19; Guanidines; Humans; SARS-CoV-2; Treatment Outcome | 2023 |
31 other studies available for nafamostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; COVID-19; COVID-19 Drug Treatment; C | 2021 |
Identification of potent inhibitors against transmembrane serine protease 2 for developing therapeutics against SARS-CoV-2.
Topics: COVID-19; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inh | 2022 |
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Topics: Animals; Benzamidines; Benzothiazoles; Cell Line; COVID-19; COVID-19 Drug Treatment; Drug Design; Ep | 2021 |
Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Topics: Animals; Benzamidines; COVID-19; COVID-19 Drug Treatment; Guanidines; Illness Behavior; Imidazoles; | 2022 |
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2.
Topics: Antibodies; Benzamidines; Blood-Brain Barrier; Central Nervous System; COVID-19; Endothelial Cells; | 2022 |
Nafamostat-Mediated Inhibition of SARS-CoV-2 Ribosomal Frameshifting Is Insufficient to Impair Viral Replication in Vero Cells. Comment on Munshi et al. Identifying Inhibitors of -1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses.
Topics: Animals; Benzamidines; Chlorocebus aethiops; COVID-19; Frameshifting, Ribosomal; Guanidines; Humans; | 2022 |
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
Topics: Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antibo | 2022 |
Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors.
Topics: COVID-19; Gabexate; Humans; Listeria monocytogenes; Mesylates; Peptide Hydrolases; Protease Inhibito | 2023 |
In Silico and In Vitro Evaluation of Some Amidine Derivatives as Hit Compounds towards Development of Inhibitors against Coronavirus Diseases.
Topics: Antiviral Agents; Benzamidines; COVID-19; Humans; Middle East Respiratory Syndrome Coronavirus; SARS | 2023 |
Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model.
Topics: Animals; Antiviral Agents; COVID-19; Disease Models, Animal; Glycyrrhizic Acid; Humans; Mice; Pandem | 2023 |
A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
Topics: COVID-19; Guanidines; Humans; SARS-CoV-2; Serine Endopeptidases | 2023 |
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
Topics: Animals; Chemoprevention; COVID-19; Cricetinae; Mesocricetus; RNA, Viral; SARS-CoV-2 | 2023 |
Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system.
Topics: Animals; COVID-19; Drug Repositioning; Humans; Liposomes; Lung; Mice; Pandemics; SARS-CoV-2; Tissue | 2023 |
Potential of heparin and nafamostat combination therapy for COVID-19.
Topics: Anticoagulants; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Guanid | 2020 |
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Topics: Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Guanidines; Pandemics; Peptidyl-Dip | 2020 |
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Cells, Cultured; Coronavirus 229E, Human; Coronavir | 2020 |
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
Topics: Aged; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Guanidines; Humans; Male; Oxy | 2020 |
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticoagulants; | 2020 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidine | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illne | 2020 |
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coro | 2020 |
SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Topics: Amino Acid Sequence; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Benzamidines; Betac | 2020 |
Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate.
Topics: Aged; Anticoagulants; Benzamidines; COVID-19; COVID-19 Drug Treatment; Female; Fibrin Fibrinogen Deg | 2021 |
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Gabexate; | 2020 |
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
Topics: Aged; Anticoagulants; Benzamidines; Blood Coagulation; COVID-19; Disseminated Intravascular Coagulat | 2021 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; C | 2021 |
Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Topics: Antiviral Agents; Benzamidines; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guani | 2021 |
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinica | 2021 |
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.
Topics: Antiviral Agents; Azithromycin; Benzamidines; Cell Line; COVID-19; COVID-19 Drug Treatment; Guanidin | 2021 |
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment.
Topics: Antiviral Agents; Benzamidines; Binding Sites; Catalytic Domain; COVID-19; COVID-19 Drug Treatment; | 2021 |